This episode was recorded on March 2nd, 2021

Dr. Roland Griffiths, Ph.D., is a professor of neuroscience, psychiatry, and behavioral science and director of the Psychedelic and Consciousness Research at Johns Hopkins University School of Medicine. He is the author of over 400 scientific research publications and has trained more than 50 postdoctoral research fellows. He has been a consultant to the National Institutes of Health and numerous pharmaceutical companies in the development of new psychotropic drugs.

Dr. Roland Griffiths and I discuss the research with John Hopkins University. We spoke about how he got into psychedelics and convinced ethic committees to approve such research, why he chose the scientific path, specifics about his studies with psilocybin, transformations of cancer patients with family members, the impact of psilocybin in existing institutions, the ongoing studies he is performing with long-time meditators and religious leaders, how the integration of psilocybin into society may look and more.

At the Center for Psychedelic and Consciousness Research, researchers focus on how psychedelics affect behavior, mood, cognition, brain function, and biological markers of health. Upcoming studies will determine the effectiveness of psilocybin as a new therapy for opioid addiction, Alzheimer's disease, post-traumatic stress disorder (PTSD), post-treatment Lyme disease syndrome (formerly known as chronic Lyme disease), anorexia nervosa and alcohol use in people with major depression. The researchers hope to create precision medicine treatments tailored to the specific needs of individual patients.